[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Foundation for Orthopaedics and Regenerative Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":493},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,43,68,91,111,131,151,174,194,213,233,252,273,293,315,342,359,378,396,415,435,454,472],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100610372","phase-1-patients-with-congenital-myasthenic-syndrome-will-be-treated-with-mesenchymal-stem-cell-exosome-solution-100610372",false,"NCT07226726","Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution","Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome","Inclusion Criteria:\n\n* Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician.\n* Patients must be able to provide informed consent, or have a guardian who does.\n* Patient must be able to travel to the site of treatment.\n\nExclusion Criteria:\n\n* Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.",[26],"Congenital Myasthenic Syndrome",[28,29,26],"exosomes","secretome","RECRUITING","2025-11-06",{"date":33,"type":34},"2025-11-10","ACTUAL",{"date":36,"type":34},"2025-01-01",{"date":38,"type":20},"2028-12-31",{"name":40,"class":41},"The Foundation for Orthopaedics and Regenerative Medicine","OTHER",3,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100450606","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cells-for-oa-100450606","NCT05147675","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for OA","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Osteoarthritis","Inclusion Criteria:\n\n* Diagnosis of Osteoarthritis\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":51,"type":20},92,[23],"This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells delivered intravenously and intraarticularly for the treatment of Osteoarthritis.",[55,56],"Osteoarthritis","Spinal Arthritis",[55,58,56],"stem cell treatment","2025-06-05",{"date":61,"type":34},"2025-06-10",{"date":63,"type":34},"2022-12-01",{"date":65,"type":20},"2027-12-01",{"name":40,"class":41},2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100451409","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cells-for-skin-ulcer-100451409","NCT05158127","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Skin Ulcer","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Skin Ulcer","Inclusion Criteria:\n\n* Diagnosis of Skin Ulcer\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":19,"type":20},[23],"This trial will study the safety and efficacy of intravenous infusion and intralesional injection of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Skin Ulcer",[79],"Skin Ulcer",[79,58],"NOT_YET_RECRUITING","2025-04-15",{"date":84,"type":34},"2025-04-17",{"date":86,"type":20},"2025-12",{"date":88,"type":20},"2028-12",{"name":40,"class":41},1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":90},"100450968","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-exosomes-for-parkinsons-disease-100450968","NCT05152394","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosome Intranasal Instillation for the Treatment of Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosis of Parkinson's Disease\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur\n* Anticoagulation medicine use",{"count":19,"type":20},[23],"This trial will study the safety and efficacy of intranasal instillation of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes for the treatment of Parkinson's Disease",[102],"Parkinson Disease",[104,58],"Parkinson's Disease",{"date":84,"type":34},{"date":107,"type":34},"2024-08-17",{"date":109,"type":20},"2027-01",{"name":40,"class":41},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":119,"briefSummary":120,"conditions":121,"keywords":125,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":130,"locationsCount":90},"100450614","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-stem-cells-for-peyronies-disease-ed-and-interstitial-cystitis-100450614","NCT05147779","Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Peyronie's Disease, Erectile Dysfunction, and Interstitial Cystitis","Inclusion Criteria:\n\n* Diagnosis of Peyronie's Disease, erectile dysfunction, or Interstitial Cystitis\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":19,"type":20},[23],"This trial will study the safety and efficacy of intravenous and intracavernosal or interstitial delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Peyronie's disease, erectile dysfunction , and Interstitial Cystitis",[122,123,124],"Erectile Dysfunction","Peyronie's Disease","Interstitial Cystitis",[122,123,58,124],{"date":84,"type":34},{"date":128,"type":34},"2021-09-12",{"date":86,"type":20},{"name":40,"class":41},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":144,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":90},"100450966","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-stem-cells-exosomes-for-trigeminal-neuralgia-100450966","NCT05152368","Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells Exosomes for Trigeminal Neuralgia","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells Exosomes for the Treatment of Trigeminal Neuralgia","Inclusion Criteria:\n\n* Diagnosis of Trigeminal Neuralgia or Peripheral Neuropathy\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":19,"type":20},[23],"This trial will study the safety and efficacy of instillation of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes for the treatment of Trigeminal Neuralgia.",[142,143],"Peripheral Neuropathy","Trigeminal Neuralgia",[142,143,58],{"date":84,"type":34},{"date":147,"type":34},"2022-09-09",{"date":149,"type":20},"2026-01",{"name":40,"class":41},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":160,"conditions":161,"keywords":168,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":173,"locationsCount":67},"100450608","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cells-for-naion-100450608","NCT05147701","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Non-arteritic Ischemic Optic Neuropathy","Inclusion Criteria:\n\n* Diagnosis of NAION (non-arteritic ischemic optic neuropathy)\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":19,"type":20},[23],"This trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of non-arteritic ischemic optic neuropathy",[162,163,164,165,166,167],"Eye Diseases","Retinitis Pigmentosa","Diabetic Retinopathy","Macular Degeneration","Traumatic Optic Neuropathy","Optic Atrophy",[162,163,58,164,165,166,167],{"date":84,"type":34},{"date":171,"type":34},"2022-02-01",{"date":149,"type":20},{"name":40,"class":41},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":21,"phases":182,"briefSummary":183,"conditions":184,"keywords":188,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":90},"100450607","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cells-for-pulmonary-diseases-100450607","NCT05147688","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Pulmonary Diseases","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Pulmonary Diseases","Inclusion Criteria:\n\n* Diagnosis of pulmonary disease\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":19,"type":20},[23],"This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Pulmonary Diseases",[185,186,187],"Pulmonary Disease","Asthma","Chronic Obstructive Pulmonary Disease",[185,186,58,187],{"date":84,"type":34},{"date":191,"type":34},"2021-12-01",{"date":86,"type":20},{"name":40,"class":41},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":21,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":210,"leadSponsor":212,"locationsCount":67},"100451407","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-exosome-intranasal-instillations-for-stroke-100451407","NCT05158101","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosome Intranasal Instillations for Stroke","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosome Intranasal Instillations for the Treatment of Stroke","Inclusion Criteria:\n\n* Diagnosis of Stroke\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":202,"type":20},15,[23],"This trial will study the safety and efficacy of intranasal instillation of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes for the treatment of Stroke",[206],"Stroke",[206,58],{"date":84,"type":34},{"date":171,"type":34},{"date":211,"type":20},"2026-02",{"name":40,"class":41},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":221,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":232,"locationsCount":67},"100440706","phase-1-safety-of-cultured-autologous-adult-adipose-derived-mesenchymal-stem-cell-versus-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-intrathecal-injection-for-sci-100440706","NCT05018793","Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Versus Cultured Allogeneic Adult Umbilical-cord Derived Mesenchymal Stem Cell Intrathecal Injection for SCI","Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Versus Cultured Allogeneic Adult Umbilical-cord Derived Mesenchymal Stem Cell Intrathecal Injection for the Treatment of Spinal Cord Injury","Inclusion Criteria:\n\n* Diagnosis of Spinal Cord Injury\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Anticoagulation medicine use\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Previous organ transplant\n* Hypersensitivity to sulfur\n* Continued drug abuse\n* Pre-menopausal women not using contraception",{"count":202,"type":20},[23],"This trial will study the safety and efficacy of intrathecal injection of cultured autologous adult adipose derived mesenchymal stem cells versus cultured allogeneic adult umbilical-cord derived mesenchymal stem cells for the treatment of spinal cord injury",[224],"Spinal Cord Injuries",[226,227,58],"spinal cord injury","SCI",{"date":84,"type":34},{"date":230,"type":34},"2024-12-01",{"date":88,"type":20},{"name":40,"class":41},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":249,"leadSponsor":251,"locationsCount":90},"100440709","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-intravenous-infusion-for-tbi-100440709","NCT05018832","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for TBI","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Traumatic Brain Injury","Inclusion Criteria:\n\n* Diagnosis of traumatic brain injury\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur\n* Seizure disorders",{"count":19,"type":20},[23],"This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of traumatic brain injury",[244],"Traumatic Brain Injury",[246,58],"Traumatic brain injury",{"date":84,"type":34},{"date":86,"type":20},{"date":250,"type":20},"2028-11",{"name":40,"class":41},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":21,"phases":260,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":90},"100440555","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-intravenous-infusion-for-ipf-100440555","NCT05016817","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Idiopathic Pulmonary Fibrosis","Inclusion Criteria:\n\n* Diagnosis of Idiopathic Pulmonary Fibrosis\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":19,"type":20},[23],"This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Idiopathic pulmonary fibrosis",[263],"Idiopathic Pulmonary Fibrosis",[263,265,58],"IPF","2025-04-14",{"date":84,"type":34},{"date":269,"type":34},"2022-07-03",{"date":271,"type":20},"2025-11",{"name":40,"class":41},{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":21,"phases":281,"briefSummary":282,"conditions":283,"keywords":285,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":292,"locationsCount":90},"100440710","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-intravenous-infusion-for-ckd-100440710","NCT05018845","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CKD","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Chronic Kidney Disease.","Inclusion Criteria:\n\n* Diagnosis of Chronic Kidney Disease\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":19,"type":20},[23],"This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Chronic Kidney Disease.",[284],"Chronic Kidney Diseases",[286,58,287],"Renal Failure","Kidney Disease",{"date":84,"type":34},{"date":290,"type":34},"2021-11-06",{"date":271,"type":20},{"name":40,"class":41},{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":21,"phases":301,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":67},"100439565","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-intravenous-infusion-for-ibd-100439565","NCT05003947","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IBD","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Inflammatory Bowel Disease","Inclusion Criteria:\n\n* Diagnosis of Crohn's disease or Ulcerative Colitis\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":202,"type":20},[23],"This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of inflammatory bowel disease",[304],"Inflammatory Bowel Diseases",[306,304,58],"IBD","2025-04-08",{"date":309,"type":34},"2025-04-10",{"date":311,"type":34},"2022-06-11",{"date":313,"type":20},"2025-10",{"name":40,"class":41},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":322,"minAge":17,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":325,"conditions":326,"keywords":330,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":67},"100527112","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cells-for-pcos-100527112","NCT06143527","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for PCOS","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Polycystic Ovary Syndrome","Inclusion Criteria:\n\n• Ultrasound documented poly cystic ovary syndrome\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety\n* Continued drug abuse\n* Previous organ transplant\n* Hypersensitivity to sulfur\n* Inability to supply proper informed consent","FEMALE",{"count":19,"type":20},[23],"This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.",[327,328,329],"Polycystic Ovary Syndrome (PCOS)","Polycystic Ovary Syndrome","PCOS",[327,328,329,331,332,333,334],"Stem Cell","Stem Cells","Mesenchymal Stem Cells","Umbilical Cord Derived Mesenchymal Stem Cells","2025-04-04",{"date":307,"type":34},{"date":338,"type":34},"2023-11-16",{"date":340,"type":20},"2027-11-16",{"name":40,"class":41},{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":21,"phases":350,"briefSummary":351,"conditions":352,"keywords":353,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":358,"locationsCount":67},"100450960","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cells-for-sci-100450960","NCT05152290","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for SCI","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury","Inclusion Criteria:\n\n* Diagnosis of Spinal Cord Injury\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur\n* Anticoagulation medicine use",{"count":19,"type":20},[23],"This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Spinal Cord Injury.",[224],[226,227,58],{"date":307,"type":34},{"date":356,"type":34},"2022-07-06",{"date":149,"type":20},{"name":40,"class":41},{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":21,"phases":367,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":375,"leadSponsor":377,"locationsCount":67},"100440711","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-intravenous-infusion-for-lupus-100440711","NCT05018858","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Lupus","Inclusion Criteria:\n\n* Diagnosis of Lupus\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":202,"type":20},[23],"This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Lupus",[370],"Lupus",[370,372,58],"Lupus Arthritis",{"date":307,"type":34},{"date":86,"type":20},{"date":376,"type":20},"2028-10",{"name":40,"class":41},{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":21,"phases":386,"briefSummary":387,"conditions":388,"keywords":390,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":395,"locationsCount":42},"100439566","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-intravenous-infusion-for-autism-100439566","NCT05003960","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Autism","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Autism","Inclusion Criteria:\n\n* Diagnosis of Autism\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety\n* Previous organ transplant\n* Seizure disorder\n* Hypersensitivity to sulfur",{"count":202,"type":20},[23],"This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Autism",[389],"Autism",[389,58],{"date":307,"type":34},{"date":393,"type":34},"2022-01-23",{"date":65,"type":20},{"name":40,"class":41},{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":21,"phases":404,"briefSummary":405,"conditions":406,"keywords":408,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":414,"locationsCount":67},"100439522","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-intravenous-infusion-for-ms-100439522","NCT05003388","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Multiple Sclerosis","Inclusion Criteria:\n\n* Diagnosis of Multiple Sclerosis\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":202,"type":20},[23],"This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of multiple sclerosis",[407],"Multiple Sclerosis",[407,409,58],"MS",{"date":307,"type":34},{"date":412,"type":34},"2021-06-26",{"date":313,"type":20},{"name":40,"class":41},{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":21,"phases":423,"briefSummary":424,"conditions":425,"keywords":427,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":67},"100440554","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-iv-infusion-for-systemic-sclerosis-100440554","NCT05016804","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Systemic Sclerosis","Inclusion Criteria:\n\n* Diagnosis of Systemic Sclerosis\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":19,"type":20},[23],"This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Systemic Sclerosis",[426],"Systemic Sclerosis",[426,428,58],"Scleroderma",{"date":307,"type":34},{"date":431,"type":34},"2022-07-04",{"date":433,"type":20},"2026-11",{"name":40,"class":41},{"id":436,"slug":437,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":21,"phases":443,"briefSummary":444,"conditions":445,"keywords":447,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":451,"leadSponsor":453,"locationsCount":67},"100440708","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-intravenous-infusion-for-cp-100440708","NCT05018819","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CP","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Cerebral Palsy","Inclusion Criteria:\n\n* Diagnosis of Cerebral Palsy\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety\n* Previous organ transplant\n* Seizure disorder\n* Hypersensitivity to sulfur",{"count":202,"type":20},[23],"This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Cerebral Palsy",[446],"Cerebral Palsy",[446,448,58],"CP",{"date":307,"type":34},{"date":171,"type":34},{"date":452,"type":20},"2027-11",{"name":40,"class":41},{"id":455,"slug":456,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":21,"phases":462,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":67},"100439564","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-intravenous-infusion-for-ra-100439564","NCT05003934","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for RA","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Rheumatoid Arthritis","Inclusion Criteria:\n\n* Diagnosis of Rheumatoid Arthritis\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":19,"type":20},[23],"This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Rheumatoid Arthritis",[465],"Rheumatoid Arthritis",{"date":307,"type":34},{"date":468,"type":34},"2021-11-07",{"date":470,"type":20},"2026-09",{"name":40,"class":41},{"id":473,"slug":474,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":21,"phases":481,"briefSummary":482,"conditions":483,"keywords":485,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":492,"locationsCount":42},"100440704","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cell-intravenous-infusion-for-aging-frailty-100440704","NCT05018767","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Aging Frailty","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Aging Frailty","Inclusion Criteria:\n\n* Diagnosis of Aging Frailty\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":480,"type":20},86,[23],"This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Aging Frailty",[484],"Frailty",[484,58,486],"Anti Aging","2025-04-02",{"date":335,"type":34},{"date":490,"type":34},"2022-01-22",{"date":65,"type":20},{"name":40,"class":41},""]